A hermetically sealed noradrenaline drug product in an intravenous ready to use translucent or transparent collapsible drip bag having low subvisible particle counts comprising: a) a headspace consisting essentially of an inert gas and < 2% v/v oxygen; and b) a liquid solution comprising: i) noradrenaline or a pharmaceutically acceptable salt thereof at a concentration of from 0.001 to 0.2 mg/ml or from 0.001 to 0.035 mg/ml, ii) less than 600 ppbw oxygen, iii) ≤ 25 per mL subvisible particles equal to or greater than 10 μm, and iv) ≤ 3 per mL subvisible particles equal to or greater than 25 μm; wherein: i) the concentration of noradrenaline or pharmaceutically acceptable salt is based on the weight of the free base of noradrenaline; ii) the subvisible particle count is determined by the light obscuration particle count test in USP <788> (May 1, 2013); iii) the oxygen content in the headspace and solution is measured immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; iv) the particle counts are observed immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; v) the drug product is free of antioxidants and chelating agents. a) a headspace consisting essentially of an inert gas and < 2% v/v oxygen; and b) a liquid solution comprising: i) noradrenaline or a pharmaceutically acceptable salt thereof at a concentration of from 0.001 to 0.2 mg/ml or from 0.001 to 0.035 mg/ml, ii) less than 600 ppbw oxygen, iii) ≤ 25 per mL subvisible particles equal to or greater than 10 μm, and iv) ≤ 3 per mL subvisible particles equal to or greater than 25 μm; wherein: i) the concentration of noradrenaline or pharmaceutically acceptable salt is based on the weight of the free base of noradrenaline; ii) the subvisible particle count is determined by the light obscuration particle count test in USP <788> (May 1, 2013); iii) the oxygen content in the headspace and solution is measured immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; iv) the particle counts are observed immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; v) the drug product is free of antioxidants and chelating agents. i) noradrenaline or a pharmaceutically acceptable salt thereof at a concentration of from 0.001 to 0.2 mg/ml or from 0.001 to 0.035 mg/ml, ii) less than 600 ppbw oxygen, iii) ≤ 25 per mL subvisible particles equal to or greater than 10 μm, and iv) ≤ 3 per mL subvisible particles equal to or greater than 25 μm; i) the concentration of noradrenaline or pharmaceutically acceptable salt is based on the weight of the free base of noradrenaline; ii) the subvisible particle count is determined by the light obscuration particle count test in USP <788> (May 1, 2013); iii) the oxygen content in the headspace and solution is measured immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; iv) the particle counts are observed immediately after the product is hermetically sealed or after the oxygen content in the headspace and solution has reached equilibrium; v) the drug product is free of antioxidants and chelating agents. <EOS>